Structural Determinants Influencing the Potency and Selectivity of Indazole-Paroxetine Hybrid G Protein-Coupled Receptor Kinase 2 Inhibitors

Renee Bouley, Helen V. Waldschmidt, M. Claire Cato, Alessandro Cannavo, Jianliang Song, Joseph Y. Cheung, Xin-Qiu Yao, Walter J. Koch, Scott D. Larsen, and John J. G. Tesmer

Running Title Page

a) Indazole-Paroxetine GRK2 Inhibitor Structural Analysis

b) Corresponding author:
   John J. G. Tesmer
   210 Washtenaw Ave Rm 3435
   Ann Arbor, MI 48198
   Tel. 734-615-9544
   Fax 734-763-6492
   Email: tesmerjj@umich.edu

c) Number of text pages: 33
   Number of tables: 5
   Number of figures: 5
   Number of schemes: 3
   Number of references: 32
   Number of words in abstract: 244
   Number of words in introduction: 750
   Number of words in discussion: 877

d) List of nonstandard abbreviations: AUC, area under the curve; BSA, buried surface area; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; MLM, mouse liver microsomes; PCA, principal component analysis; PK, pharmacokinetics; PKA, protein kinase A; ROCK1, Rho-associated coiled-coil containing kinase 1; r.m.s.d., root mean squared deviation.
Abstract

G protein-coupled receptor kinases (GRKs) phosphorylate activated receptors to promote arrestin binding, decoupling from heterotrimeric G proteins, and internalization. GRK2 and GRK5 are overexpressed in the failing heart and thus have become therapeutic targets. Previously, we discovered two classes of GRK2-selective inhibitors, one stemming from GSK180736A, a ROCK1 inhibitor, and the other from paroxetine, a selective serotonin-reuptake inhibitor. These two classes of compounds bind to the GRK2 active site in a similar configuration, but contain different hinge-binding “warheads”: indazole and benzodioxole, respectively. We surmised from our prior studies that an indazole would be the stronger hinge binder, and would impart increased potency when substituted for benzodioxole in paroxetine derivatives. To test this hypothesis, we synthesized a series of hybrid compounds that allowed us to compare the effects of inhibitors that differ only in the identity of the warhead. The indazole-paroxetine analogs were indeed more potent than their respective benzodioxole derivatives but lost selectivity. To investigate how these two warheads dictate selectivity, we determined crystal structures of three of the indazole hybrid compounds (CCG224061, CCG258284, and CCG258748) in complex with GRK2–Gβγ. Comparison of these structures with those of analogous benzodioxole-containing complexes confirmed that the indazole-paroxetine hybrids form stronger interactions with the hinge of the kinase, but also stabilize a distinct conformation of the kinase domain of GRK2 compared to previous complexes with paroxetine analogs. This conformation is analogous to that which can be assumed by GRK5, at least partially explaining the loss in selectivity.
Introduction

Heart failure is broadly described as an inability of the heart to effectively pump and supply blood to the body. In response to insufficient blood flow, the sympathetic nervous system produces increased amounts of catecholamines to stimulate β-adrenergic receptors, which are part of the G protein-coupled receptor (GPCR) superfamily (Salazar et al., 2007; Belmonte and Blaxall, 2011). However, the prolonged stimulation of GPCRs initiates the upregulation and phosphorylation by GPCR kinases (GRKs), which targets these receptors for arrestin binding and internalization (Ferguson et al., 1996; Ribas et al., 2007). Receptor internalization reduces the number of receptors present on the cell surface, thus diminishing the responsiveness to agonists (Ferguson et al., 1996).

There are seven different GRKs found in humans, which are divided into the GRK1 (GRK1 and 7), GRK2 (GRK2 and 3), and GRK4 (GRK4, 5, and 6) subfamilies, all of which belong of the protein kinase A, G, and C (AGC) family of Ser/Thr protein kinases. GRKs 2 and 5 are the dominant GRKs in the myocardium and are upregulated during heart failure (Dzimiri et al., 2004; Montó et al., 2012). A series of studies have shown that selective inhibition of GRK2 activity is a promising approach to improve cardiac function during heart failure (Rockman et al., 1998; Raake et al., 2013; Schumacher et al., 2015).

We previously identified paroxetine, an FDA-approved serotonin-reuptake inhibitor, and GSK180736A (Figure 1) as GRK2 inhibitors (Thal et al., 2012; Homan et al., 2015). Co-crystal complexes of these compounds bound to GRK2 revealed that they both bind similarly in the active site (Figure 2a) (Thal et al., 2012; Homan et al., 2015). The A rings of both compounds occupy the adenine subsite and bind the hinge (Figure 2a). The core of the scaffold (ring B), either a dihydropyrimidine (GSK180736A) or piperidine (paroxetine), occupies the ribose
subsite while the C ring occupies the polyphosphate subsite. However, neither occupy the hydrophobic pocket of the active site as was observed with the Takeda compound (Figure 2b) known as CMPD101 or compound 115h (Ikeda et al., 2007; Thal et al., 2011; Okawa et al., 2017). We subsequently used a rational drug design approach to generate derivatives of both GSK180736A and paroxetine with substituents appended onto the C ring via an amide linker in order to occupy the hydrophobic pocket (Waldschmidt et al., 2016, 2017).

We hypothesized that due to the similar binding modes of GSK180736A and paroxetine (Figure 2), their structure-activity relationships would be translatable. Although this turned out generally not to be the case, overall the addition of amide-linked D-ring substituents to these scaffolds did lead to increases in potency in each class. In the case of GSK180736A, several substituents enabled us to build in selectivity for GRK2 over other kinases, especially Rho-associated coiled-coil containing kinase 1 (ROCK1) for which this compound was originally designed to inhibit (Sehon et al., 2008). We were also interested in understanding if the hinge-binding moiety, an indazole in the case of GSK180736A and a benzodioxole in the case of paroxetine, was interchangeable. However, it was observed in the case of the GSK180736A scaffold that exchanging the indazole for a benzodioxole resulted in a severe loss of activity (Waldschmidt et al., 2016).

We next hypothesized that by exchanging the benzodioxole moiety in the paroxetine scaffold with an indazole would instead result in increased potency due to its stronger interactions with the hinge (two hydrogen bonds for indazole versus a hydrogen bond and a carbon-oxygen hydrogen bond for benzodioxole). Thus, we synthesized a series of paroxetine hybrids in which the benzodioxole ring was exchanged for indazole. These indazole-paroxetine hybrids in general showed an increase in GRK2 potency relative to their benzodioxole...
counterparts, however lost selectivity. To understand the molecular basis for enhanced potency and loss of selectivity, we crystallized several of these hybrid compounds in complex with GRK2–Gβγ. These and prior crystallographic studies show that the indazole warhead locks the kinase domain into a specific conformation that leads to one particular crystal form, whereas the benzodioxole-based compounds lead to a variety of crystal forms with subtly different conformations of the kinase domain. Our results indicate that the identity and strength of the hinge-binding moiety is important for dictating the overall conformation of the GRK2 kinase domain, and that weaker hinge interactions allow access to a broader distribution of subtly different conformational states. The selectivity generally exhibited by benzodioxole-based compounds for GRK2 may therefore result from the ability of its kinase domain to access conformational states not readily available to closely related enzymes.
Materials and Methods

Synthesis. Synthetic procedures are provided in the supplemental data. $^1$H NMR spectra were taken in DMSO-d$_6$, MeOD, or CDCl$_3$ at room temperature on Varian Inova 400 MHz or Varian Inova 500 MHz instruments. Reported chemical shifts for the $^1$H NMR spectra were recorded in parts per million (ppm) on the $\delta$ scale from an internal standard of residual tetramethylsilane (0 ppm). Mass spectrometry data was measured using a Waters Corporation Micromass LCT or Agilent6230 Q-TOF. HPLC was used to determine purity of biologically tested compounds on an Agilent 1100 series with an Agilent Zorbax Eclipse Plus–C18 column. A gradient of 10-90% acetonitrile/water over 6 min followed by 90% acetonitrile/water for 7 min was used with detection at 254 nm. All tested compounds had purity >95%.

Kinase Assays. PKA and ROCK1 inhibition was assayed using the ADP-Glo Kinase Assay system (Promega, Madison, WI) as previously described (Homan et al., 2015). Compounds were tested against PKA in duplicate using an 8-point concentration range and the experiment repeated in triplicate on separate days. Compounds were screened at 10 µM for ROCK1 inhibition in triplicate and the experiment repeated in triplicate on separate days and the percent inhibition was calculated. A BMG Labtech PHERAsar imaging system was used to measure luminescence. Inhibition of GRK1, 2, and 5 was determined in 20 mM HEPES pH 7.0, 2 mM MgCl$_2$, and 0.025% DDM with 50 nM of the respective GRK and 500 nM tubulin. Kinetic reactions were initiated by the addition of [$\gamma$-$^{32}$P]ATP (500 µCi, 5 µM), allowed to proceed for 5 min and quenched by the addition of SDS loading buffer. Each compound was tested in duplicate using an 8-point concentration range and the experiment repeated in triplicate on separate days. Samples were then separated by SDS-PAGE and gels were dried and exposed with a phosphorimaging screen. The images were then scanned with a Typhoon imager and quantified.
using ImageQuant, as previously described (Thal et al., 2012). Data was fit to a three-parameter
dose-inhibitor response curve with a fixed Hill slope of 1 and the bottom constrained to 0 using
GraphPad Prism. A maximum of two outliers were removed per individual dataset and in some
cases an entire dataset was excluded from the analysis.

**Mouse Liver Microsome Assays.** Metabolic stability was determined using CD-1 mouse
liver microsomes. Reactions consisted of 1 µM compound, 0.5 mg/mL microsomes, 1.7 mM
NADPH in 0.1 M phosphate buffer pH 7.4 supplemented with 3.3 mM MgCl₂, incubated at 37
°C. Aliquots of 40 µL were taken at 0, 5, 10, 15, 30, 45, and 60 min and quenched in 3 volumes
of cold acetonitrile containing 100 ng/mL internal standard. Samples were centrifuged at 15,000
rpm for 10 min and the supernatant was analyzed by LC-MS/MS.

**Protein Expression and Purification.** Human GRK2 S670A with a C-terminal
hexahistidine tag was expressed in High-Five cells using the Bac-to-Bac insect cell expression
system (Life Technologies, Carlsbad, CA). Cells were harvested 48 h post infection and lysed.
GRK2 was purified from the clarified lysate as described previously for GRK1 using nickel-
nitrilotriacetic acid affinity and cation exchange chromatography (Singh et al., 2008). Fractions
containing GRK2 were pooled and further purified on a Sephadex 200 column into 20 mM
HEPES pH 7.5, 100 mM NaCl, and 1 mM DTT. Soluble human Gβ₁γ₂ (C68S mutant) containing
an N-terminal (on the Gβ₁ unit) hexahistidine tag was expressed using a dual-promoter insect
cell expression vector in High-Five cells. The cells were harvested 48 h post infection and lysed.
Gβ₁γ₂ was purified from the clarified lysate as described previously using nickel-nitrilotriacetic
acid affinity and anion exchange chromatography (Kozasa, 2004). Fractions containing Gβ₁γ₂
were pooled and further purified on a Sephadex 200 column into 20 mM HEPES pH 8.0, 100
mM NaCl, and 1 mM DTT.
Crystal Structure Determination. Purified GRK2 (S670A) and soluble G\(\beta\)1\(\gamma\)2 (C68S) were mixed in a 1.2:1 molar ratio with a final protein concentration of approximately 10 mg/mL. Inhibitor (500 \(\mu\)M) and MgCl\(_2\) (2 mM) were added to the protein mixture and allowed to incubate on ice for 30 min prior to filtration through a 0.2 \(\mu\)m Nanosep centrifugal device (Pall Laboratory, Port Washington, NY). Inhibitor complexes were crystallized as previously described by hanging drop vapor diffusion at 4 °C with drops consisting of 0.8 \(\mu\)L protein and 0.8 \(\mu\)L reservoir solution, which consisted of 50 mM MES pH 6.0, 0.8-1.2 M NaCl, and 8-16% PEG3350 (Thal et al., 2011, 2012). Crystals generally appeared after 2-3 days and grew for 1-2 weeks. Crystals were harvested in a cryoprotectant solution consisting of the reservoir solution supplemented with 25% ethylene glycol and 500 \(\mu\)M inhibitor before being flash frozen in liquid nitrogen. Diffraction data was collected on the LS-CAT beamlines 21-ID-G and 21-ID-D at wavelengths of 0.97857 and 1.0332 Å, respectively. Data integration and scaling was performed with XDS (Sauter et al., 2013) or DIALS (Gildea et al., 2014). The structures were solved using Phaser (McCoy et al., 2007) with PDB ID 4PNK as the search model. Reciprocal-space refinement was performed with PHENIX (Afonine et al., 2012) and alternated with local real-space refinement and model building using Coot (Emsley and Cowtan, 2004). Crystal refinement statistics are listed in Supplementary Table 1. The final models were validated using MolProbity (Chen et al., 2010) prior to deposition in the Protein Data Bank under accession codes: 5WG3, 5WG4, and 5WG5.

Principal Component Analysis. Principal component analysis was previously performed for the kinase domains of PKA, GRK1, GRK4 family members, and GRK2 that were previously deposited on the Protein Data Bank (Yao et al., 2017). The kinase domains were aligned using core residues which were identified to be structurally invariant. Previous structural analysis of 49
GRK and 201 PKA structures revealed two distinct structural motions which were grouped into PC1 (72% of the structural variance) and PC2 (approximately 10% of the structural variance). These structural motions corresponded to an opening and closing of the kinase domain mediated by the hinge connecting the small and large lobes (PC1) and a twisting motion between these domains (PC2). The GRK2 structures from this study were incorporated into the same analysis to benchmark their conformational states with respect to these previously published structures.

**Myocyte Shortening Assays.** Mouse cardiomyocytes were isolated from left-ventricular free wall and septum of C57/Bl6 mice as previously described (Song et al., 2008). Cells were used within 2-8 h of isolation and plated on laminin-coated coverslips and bathed in HEPES-buffered (20 mM, pH 7.4) medium 199 containing 1.8 mM extracellular Ca\(^{2+}\). Coverslips were then mounted in the Dvorak-Stotler chamber for recording and bathed in 0.7 mL of fresh medium. Imaging was performed with a variable field-rate camera (Zeiss IM35, Ionoptix) using edge detection and sarcomere length. Peak contraction was measured as the percentage of cell shortening. Cells were paced at 1 Hz and treated with isoproterenol (0.5 \(\mu\)M) for 2 min, with pretreatment of either PBS as vehicle or CCG224061 (0.5 and 1 \(\mu\)M) for 10 min, and the contractions recorded (Thal et al., 2012).

**Mouse Pharmacokinetic Studies.** All animal experiments were approved and conducted in accordance with standards set by the University of Michigan Committee on Use and Care of Animals and Unit for Laboratory Animal Medicine (ULAM). Preliminary pharmacokinetics of CCG224061 were determined in female CD-1 mice following intraperitoneal injection at 10 mg/kg. The compound was dissolved in 15% (v/v) DMSO, 15% (v/v) PEG-400, and 70% (v/v) PBS. Blood samples of 50 \(\mu\)L were collected at 0.5, 2, 4, and 7 h, centrifuged at 3500 rpm for 10 min, and the plasma frozen at -80°C for later analysis. Plasma compound concentrations were
quantified using LC-MS/MS. The LC-MS/MS method consisted of a Shimadzu HPLC system with a Waters Xbridge-C18 column (5 cm × 2.1 mm, 3.5 μm) for chromatographic separation of the compound. An AB Sciex QTrap 4500 mass spectrometer equipped with an electrospray ionization source (ABI-Sciex, Toronto, Canada) in the positive-ion multiple reaction monitoring (MRM) mode for detection. All pharmacokinetic parameters were calculated by noncompartmental methods using WinNonLin software, version 3.2 (Pharsight Corporation, Mountain View, CA, USA).

Results

Synthesis.

Paroxetine hybrid compounds in which there is an indazole in place of the benzodioxole were prepared by a convergent approach (Scheme 1). Intermediate 7b was synthesized from commercially available 2-fluoro-5-methylphenol 1. Nitration of compound 1 proceeded first through the nitroso via sulfuric acid and sodium nitrite then nitric acid was used to afford nitro 2 (Flaugh et al., 1979). Amine 3 was readily accessed via palladium reduction of nitro 2. Acetylation followed by cyclization of the amine with isoamyl nitrite and subsequent hydrolysis yields 6-fluoro-1H-indazol-5-ol 4b (Iwakubo et al., 2007). Silyl protection of the alcohol gives 5b. In the presence of catalytic dimethylaminopyridine the indazole is then Boc-protected giving regioisomers of 6b. Final silyl deprotection gives the free alcohol 7b. Intermediate 7a was synthesized from the commercially available 1H-indazol-5-ol 4a as described for 7b.

Analogs 11a and 11b were synthesized from intermediate 8 which was obtained as previously described (Scheme 2) (Waldschmidt et al., 2017). Mesylation of alcohol 8 followed
by displacement by 7a or 7b gives intermediates 9a/b. Base mediated hydrolysis of 9a/b followed by amide coupling and Boc deprotection yields analogs 11a/b.

Synthesis of the indazole substituted non-hybrid analogs are shown in Scheme 3. Alcohol 12, which has previously been reported (Waldschmidt et al., 2017), was then N-alkylated via two different methods. The N-ethyl 13a was achieved through substitution using ethyl iodide under basic conditions. The N-isopropyl 13b was prepared through reductive amination with acetone. Respective N-substituted analogues (compound 14 is commercially available and 15 has been previously reported) were then mesylated at the benzylic alcohol which was subsequently displaced with alcohols 7a or 7b to give intermediates 16a-e. Final Boc deprotection yielded analogs 17a-e.

Structure-Activity Relationships

To investigate whether binding of paroxetine hybrids could be improved, we exchanged the benzodioxole moiety for an indazole, analogous to what is present in GSK180736A (Table 1). CCG224061 showed a 20-fold increase in potency for GRK2 (IC₅₀ = 66 nM) over paroxetine (IC₅₀ = 1.38 µM) (Thal et al., 2012). However, this change also resulted in increased activity against GRK1 and 5, PKA, and ROCK1. Although CCG224061 was still selective for GRK2, the selectivity factor over ROCK1 was only 5-fold, versus more than 50-fold selectivity observed with paroxetine (Waldschmidt et al., 2017). In an effort to improve selectivity, 2,6-dimethoxybenzylamide was appended to the fluorophenyl C-ring (CCG232406). Previously, this adduct gave the largest improvement in the GSK180736A scaffold (Waldschmidt et al., 2016). Compound CCG232406 indeed showed improvement in GRK2 selectivity over the other GRKs and PKA, and approximately 20-fold selectivity over ROCK1.
In a parallel attempt to improve selectivity, we appended two favorable adducts, 2-pyridylmethylamide and 3-pyrazolylmethylamide, discovered from our previous efforts using the paroxetine scaffold (Waldschmidt et al., 2017) to generate CCG257284 and CCG258748, respectively. CCG257284 showed no improvement in GRK2 potency relative to CCG224061 but resulted in pan-GRK inhibition with potencies similar to the analogous GSK180736A-based analog (CCG215022) (Waldschmidt et al., 2016). CCG258748 exhibited our most potent GRK2 inhibition to date with an IC$_{50}$ of 8 nM. Although this compound displayed greater than 30-fold selectivity over the other GRKs and PKA, the IC$_{50}$ for GRK5 was still quite potent at 240 nM.

Lastly, we investigated alkylating the piperidine nitrogen of CCG224061 to improve selectivity (Table 2). N-methylation (CCG258001) resulted in a 4-fold decrease in GRK2 potency but much more dramatic decreases in potency for GRK1, GRK5, and PKA, resulting in >100 fold-selectivity for GRK2 over all three kinases. Increasing the size of the methyl to ethyl and isopropyl (CCG258211 and CCG258746, respectively) was not as well tolerated, in that the GRK2 potency dropped with increasing substituent size. Therefore, larger alkyl groups were not explored.

**Metabolic Stability**

In addition to improving the in vitro potency and selectivity for GRK2 we also aimed to generate analogs with more favorable pharmacokinetic (PK) properties and thus hopefully efficacy in vivo because the paroxetine scaffold is much better tolerated than GSK180736A (Waldschmidt et al., 2017). The compounds were incubated with mouse liver microsomes (MLM) in order to test for metabolic stability (Table 1). The initial hit compound, paroxetine, had a half-life of 24.1 min in this MLM assay (Waldschmidt et al., 2017). Replacing the benzodioxole ring with an indazole (CCG224061) resulted in a longer half-life of 30.3 min.
However, CCG257584 and CCG258748 did not show any improvement in metabolic stability compared to their respective benzodioxole analogs (CCG211998 and CCG258208). We also explored fluorination of the C6 position of the indazole ring to improve potency and improve metabolic stability as this was previously shown to be successful with similar compounds (Goodman et al., 2007; Sehon et al., 2008). However, addition of a fluoro substituent to the A ring (CCG258002 and CCG258003) did not improve GRK2 potency and did not have a significant effect on the metabolic stability (Table 1).

**Crystallography**

Previously we were successful in obtaining crystals of GRK2–Gβγ complexes bound to three paroxetine analogs containing a benzodioxole warhead and paroxetine (Thal et al., 2012; Waldschmidt et al., 2017). These complexes crystallized in two different crystal forms (two C2 and one P2), whereas inhibitors based off the GSK180736A scaffold (which contain an indazole warhead) all crystallized in a C2221 crystal form (Waldschmidt et al., 2016) (Table S1). A previously reported benzolactam derivative of paroxetine (PDB ID: 4MK0), also crystallized with the same packing as the GSK180736A-based compounds (Homan et al., 2013). Therefore, we hypothesized that the identity of the hinge-binding moiety is critical for not only determining potency towards GRK2 in these compounds but also dictating the conformation of the kinase domain and consequently the crystal form. The indazole and benzolactam moieties seem to be able to form stronger hinge interactions via multiple conventional hydrogen bonds, thereby stabilizing a consistent kinase conformation that allows GRK2 to crystallize in a reproducible way (Thal et al., 2012; Homan et al., 2013, 2015).

Consistent with this reasoning, the three indazole-paroxetine hybrids (CCG224061, CCG258284, and CCG258748) co-crystallized with GRK2–Gβγ in this study also crystallized in...
the $C22_1$ space group. In all three complexes, the indazole forms two hydrogen bonds to the carbonyl oxygen of Asp272 and the backbone nitrogen of Met274 in the hinge (Figure 3). As previously observed in other paroxetine complexes, there is an additional highly conserved hydrogen bond between the piperidine nitrogen of the paroxetine scaffold and the backbone carbonyl of Ala321. As expected, the D-ring amide linker of CCG258748 and CCG257284 made additional interactions. In the case of CCG258748, the carbonyl oxygen and amide nitrogen formed hydrogen bonds with the backbone nitrogen of Gly201 and the sidechain of Asp335, respectively (Figure 3c). In the case of CCG257284 a hydrogen bond with the sidechain of Asp335 was not observed due to this residue being shifted slightly away from the ligand. Finally, in the case of CCG258748 the pyrazole is able to make additional hydrogen bonds with the sidechains of Glu239 and Lys220 that could explain its high potency (Figure 3c). The pyridine nitrogen of CCG257284 does not appear to be able to make any interactions with the protein and is modeled with the nitrogen pointing out of the active site so that it can favorably interact with solvent (Figure 3b).

**Structural Comparisons with Analogous GRK2-Inhibitor Complexes**

We have previously published complexes with paroxetine, CCG211998, and CCG258208 (PDB IDs: 3V5W, 5UKK, and 5UKM, respectively), which are the benzodioxole analogs of the complexes of CCG224061, CCG257284, and CCG258784, respectively, that we report here (Thal et al., 2012; Waldschmidt et al., 2017). Comparison of these structures thus give insights into how substituting indazole for benzodioxole in the paroxetine scaffold influences the overall conformation of the small and large lobes of the kinase domain, and therefore clues into the molecular basis for the remarkable selectivity underlying the benzodioxole-based compounds.
Alignment of the small lobes (residues 185-271) of the CCG224061 (indazole) and paroxetine (benzodioxole) complexes yielded a root mean squared deviation (r.m.s.d.) value of 0.32 Å for the Cα atoms. The two compounds superimpose almost exactly. Their A rings are slightly offset but make analogous hydrogen bonds with the hinge (to Asp272 and Met274) (Figure 4a). However, in the case of paroxetine the interaction with Asp272 is weaker because it is a CH—O hydrogen bond. In the CCG224061 complex, the backbone of the hinge is pushed out a maximum of 0.6 Å at Asn275 compared to the paroxetine complex, and the P-loop (β1-β2 turn) exhibits a more closed conformation, exhibiting a 2.1 Å difference at the Cα of Gly201. Differences were also observed in the β2-β3 and β4-β5 loops of up to 0.6 Å and 0.8 Å, respectively.

Comparison of the CCG257284 (indazole) and CCG211998 (benzodioxole) complexes yielded the largest r.m.s.d. value of the three pairs of complexes (0.70 Å). This likely reflects the unusual space group of the CCG211998 complex (P2). However, the two compounds bind similarly and their protein-ligand interactions are conserved (Figure 4b). The largest differences are observed in the A and D rings. The indazole forms stronger interactions with the hinge via shorter hydrogen bonds with the backbone of Met274 and Asp272 (3.3 and 2.8 Å versus 3.6 and 3.4 Å, respectively). The tighter interaction between the indazole and hinge is paired with a shift of the Cα of Asp272 by 0.7 Å. This propagates into a shift of the β2-β3 and β4-β5 loops of 1.0 Å and 0.9 Å, respectively. The P-loop is shifted upwards in the CCG257284 complex by up to 1.0 Å (for the Cα of Gly201) and the αB-αC loop is pushed outwards by a maximum of 1.3 Å. Additionally, a large portion of the active-site tether (AST, residues 493-500) is ordered in the CCG257284 complex relative to the CCG211998 complex.
The CCG258748 (indazole) and CCG258208 (benzodioxole) complexes displayed a r.m.s.d. deviation of 0.41 Å for the Cα atoms of the small lobe. The compounds bind similarly (Figure 4c), although the hydrogen bonds with the hinge are again stronger (shorter) in the case of CCG258748 (distances of 3.7 and 2.9 Å versus 3.8 and 3.1 Å, respectively). The hinge is displaced a maximum of 0.5 Å away from the active site in CCG258748 compared to the CCG2528208 complex. Additionally, the 3-pyrazolylmethylamide shows slightly different conformation and interactions in the hydrophobic subsite. Although in both CCG258748 and CCG258208 the two pyrazole nitrogens form hydrogen bonds with Lys220 and Glu239, CCG258208 forms an additional contact with Asp335 via its amide linker. The P-loop is shifted up to 0.6 Å at Gly201 away from the active site in the CCG258748 complex. Hinge interactions formed by CCG258748 also induce up to a 0.8 Å change of the β4-β5 loop, and a large shift in the β2-β3 loop (1.2 Å for the Cα of Asp212). There is a smaller change in the αB-αC loop compared to other analogous complexes, with a 0.7 Å shift for the Cα of Glu233. Additionally, the highly mobile AST is more ordered in the CCG258748 complex, allowing for an additional 5 residues (491-496) to be modelled.

The buried surface area (BSA) of each of these six ligands and their hinge-binding moieties was then compared (Table 5). In general, the BSA of the indazole warhead was greater than that of benzodioxole. However, the entire BSA of CCG258748 and CCG257284 was less than observed with their respective benzodioxole analogs (CCG258208 and CCG211998, respectively), due to the differences in packing of the D rings and outward movements of the αB-αC loop.

Principal component analysis (PCA) was then performed to plot the conformation of the new ligand complexes in the 2D space spanned by PC1 and PC2, in which PC1 represents a
concerted opening/closing of the kinase domain describing the largest variance across published GRK structures and PC2 is a twisting motion representing smaller structural variance (Yao et al., 2017). This approach allows us to analyze in an unbiased way the global conformational changes of the kinase domain in response to binding different classes of inhibitors (in this case indazole vs. benzodioxole warheads). As expected, this analysis showed that the GRK2 complexes with the indazole-paroxetine hybrids (CCG224061, CCG257284, and CCG258748) all cluster closely together with several previously determined indazole-containing complexes (Figure 5). More specifically, all GRK2 complexes with indazole-containing compounds display similar PC1 compositions but exhibit greater variance along the PC2 coordinate (especially for entries 5HE0 and 5HE3). The GRK2 complexes with CCG224061 and CCG257284 showed almost identical PC1/PC2 compositions and ended up very close to the CCG224406 (a GSK analog, entry 5HE2) and GSK180736A (entry 4PNK) complexes. The GRK2 complex with CCG258748 was closest to 4MK0 (complex with a benzolactam-paroxetine analog) in PC space. On the other hand, the various benzodioxole complexes inhabit a much broader spectrum of conformational space. The CCG211998 (5UKK) complex showed the smallest displacement from the mean along PC1, perhaps consistent with the fact that this was the only complex thus far to crystallize in the space group P2.

Myocyte Shortening Assays

To investigate how indazole-paroxetine hybrids perform in a more in vivo environment, we tested CCG224061 with mouse cardiomyocytes and measured their ability to produce a contraction. The cardiomyocytes were harvested from adult mice and incubated with varying doses of the inhibitors followed by a dose of the β-AR agonist isoproterenol. Paroxetine needed to be given at a dose of 10 µM in order to produce a significant response, whereas GSK180736A
showed a similar response at 1 µM (Thal et al., 2012; Waldschmidt et al., 2016) consistent with its 10-fold improvement in potency over paroxetine measured in vitro. Similarly, CCG224061 produced a significant increase in the maximum contraction response when dosed at 1 µM, consistent with its 20-fold higher potency for GRK2 compared to paroxetine (Table 3).

**Mouse Pharmacokinetic Studies**

CCG224061 was then evaluated in a rapid mouse pharmacokinetics study (Table 4). In this study, the compound was injected intraperitoneally at 10 mg/kg and plasma samples collected after 30 min, 2, 4, and 7 h. The plasma levels of compound were quantified using MS/MS and a calibration curve. At 7 h the levels of CCG224061 were still quantifiable at 13 ng/mL (0.04 µM), however this is below the IC₅₀ of 0.066 µM. This compound showed a much lower area under the curve (AUC) than CCG258208, which was previously evaluated (Waldschmidt et al., 2017). However, in the mouse liver microsome assays CCG224061 showed a 3-fold longer half-life than CCG258208. This suggests that CCG224061 may be cleared renally in addition to undergoing CYP-mediated metabolism.

**Discussion**

Understanding the molecular bases for potency and selectivity among closely related protein kinases is key to the rational design of improved GRK chemical probes. In this study, we hypothesized that substituting the benzodioxole moiety of paroxetine or its derivatives for an indazole would result in higher potency for GRK2. The hope was that they would retain the same or better selectivity as mediated by other substituents in each compound (namely the B, C and D rings). Indeed, these compounds showed corresponding increases in GRK2 potency. Additionally, this class of indazole-paroxetine hybrids showed similar metabolic stability and
efficacy in a mouse cardiomyocyte assay compared to previous paroxetine analogs. However, when CCG224061 was tested in mice it showed worse PK parameters than a previous benzodioxole analog (CCG258208) suggesting a renal clearance mechanism. The expected increase in potency was also met with corresponding increases in GRK5, PKA, and ROCK1 potency and the indazole series of compounds suffered from a 200- to 20-fold loss in selectivity compared to their benzodioxole-containing analogs.

To investigate the reasons for these changes in potency and selectivity, we determined crystal structures of GRK2–Gβγ bound to three pairs of analogs in each series. The stronger hydrogen bond interactions and small increase in BSA for the indazole moiety likely leads to stronger interactions in the adenine binding pocket next to the hinge, leading to higher stability and a well-defined kinase domain conformation that consistently leads to the same crystal form (Table S2). The indazole-paroxetine analogs that contained amide-linked D rings also appeared to further stabilize the AST region, which passes over the active site. On the other hand, selectivity conferred by the benzodioxole hinge-binding moiety seems to be due to looser interactions in the adenine pocket, as typified by weaker hydrogen bonds to the hinge (including one CH-O bond) and less BSA. GRK2 is able to alter its configuration in order to conform to each particular analog, yielding three distinct crystal forms when in complex with benzodioxole warhead ligands (one paroxetine analog not reported in this paper was observed to crystallize in C2221, the same crystal form as the indazole-hybrids). Given their highly conserved active sites, the molecular basis for selectivity for GRK2 over other GRKs and AGC kinases is therefore most easily explained by the innate ability of GRK2 to accommodate these conformational changes.
Changing the identity of the hinge-binding moiety also affects how the D-ring packs, thereby influencing the conformation of residues in the αC helix and αB-αC loop that contacts the D ring, if present. Indeed, it was observed that there was a consistent shift of the αB-αC loop away from the active site in the indazole-hybrid complexes relative to those of the benzodioxole analogs. However, in the case of the CCG258748 complex this change in the αB-αC loop is subtler, which is most likely due to the interactions formed with the pyrazole D-ring of these compounds. In particular, the hydrogen bond formed between a pyrazole nitrogen and Glu239 in αC would restrict the movement of this loop. The outward movement of the αB-αC loop would create a slightly broader active site that could accommodate larger substituents, which could explain why bulky D-ring substituents like a 2,6-dimethoxybenzylamide showed very high potency in the GSK180736A series but not in the benzodioxole-paroxetine compounds (Waldschmidt et al., 2016, 2017). Additionally, this shift of αB-αC loop may contribute to a kinase domain conformation that is more similar to that observed with other kinases such as GRK5 or PKA.

PCA revealed that the GRK2–Gβγ complexes with indazole-paroxetine hybrid analogs adopt similar kinase domain conformations as complexes with GSK180736A analogs and the benzolactam-paroxetine analog (which all crystallized in the C222₁ crystal form). Interestingly, the kinase domain conformation in these complexes is also closely related to that of GRK5 bound to sangivamycin (PDB entry 4TNB) (Komolov et al., 2015). This result could help explain why indazole-paroxetine hybrids are able to inhibit GRK5 more potently than the corresponding benzodioxole analogs, as they are able to trap the kinase domains of GRK2 and GRK5 in a similar conformational state. It should however be noted that the structure of GRK5 in complex with another indazole-based GSK180736A analog, CCG215022 (PDB entry 4WNK),
which is a pan-GRK inhibitor, adopted a distinct kinase conformation (Figure 5). Thus, the structure of a complex between GRK5 and an indazole-paroxetine hybrid would help to further elaborate on how GRK5 potency is gained. On the other hand, the benzodioxole analogs allow more conformational flexibility in the GRK2 kinase domain, as evidenced by the wider spread in PC space of 3V5W, 5UKK, 5UKM, and 5UKL, especially along the PC1 axis. This indicates once again that with respect to benzodioxole moieties, selectivity is likely driven by the apparently unique ability of GRK2 to mold itself to these ligands. Notably, another highly selective GRK2 inhibitor, CMPD101 (115h), also forms relatively weak interactions with the hinge via a pyridine moiety, and crystallized in complex with GRK2 in one of the C2 crystal forms (Thal et al., 2011; Okawa et al., 2017). Given that the unique conformational space sampled by the kinase domains of GRK2 and GRK5 seems to be a major determinant of selectivity, it will be important to take their differing landscapes into account as one looks towards the rational design of GRK5-selective inhibitors.
Acknowledgments

The mouse liver microsome stability and short pharmacokinetic studies were executed by the University of Michigan Pharmacokinetics Core.

Authorship Contributions

Bouley and Waldschmidt contributed equally.

Participated in research design: Koch, Larsen, Tesmer

Conducted experiments: Bouley, Waldschmidt, Cato, Cannavo, Yao

Contributed new reagents of analytic tools: Song, Cheung

Performed data analysis: Bouley, Waldschmidt, Cato, Cannavo, Yao

Wrote or contributed to the writing of the manuscript: Bouley, Waldschmidt, Tesmer
References


Footnotes

The work at University of Michigan was supported by the National Institutes of Health National Heart, Lung, and Blood Institute [Grants HL071818 and HL122416] to J.J.G.T.; and the American Heart Association [Grant 15PRE22730028] to H.V.W.; and the University of Michigan Chemistry-Biology Interface (CBI) training program National Institutes of Health [Grant 5T32GM008597] to M.C.C.. The work at Temple University was supported by the National Institutes of Health [Grants R37 HL061690, P01 HL075443, P01 HL108806, and P01 HL091799] to W.J.K. Use of the Advanced Photon Source was supported by the US Department of Energy, Office of Science, Office of Basic Energy Sciences, under Contract No. DE-AC02-06CH11357; and the use of LS-CAT Sector 12 was supported by the Michigan Economic Development Corporation and Michigan Technology Tri-Corridor Grant [085P1000817].

R.B. and H.V.W. made equal contributions.
Figure Legends

Figure 1. Chemical structures of GRK2 inhibitor scaffolds and activity against GRK2, GRK5, and ROCK1, expressed as either IC\(_{50}\) or percent inhibition.

Figure 2. Comparison of GRK2 inhibitor scaffolds bound in the GRK2 active site. A) Overlay of paroxetine (gray carbons) and GSK180736A (purple carbons) bound to the GRK2–G\(\beta\gamma\) complex (PDB IDs: 3V5W and 4PNK, respectively). B) Overlay of paroxetine (gray carbons) and Takeda CMPD101 (light blue carbons) bound to the GRK2–G\(\beta\gamma\) complex (PDB IDs: 3V5W and 3PVW, respectively). Ring systems are labeled according to the A, B, C, and D convention shown in Figure 1.

Figure 3. Electron density |\(F_o\)| - |\(F_c\)| omit maps contoured at 3.0 \(\sigma\) and binding modes for ligands co-crystallized with GRK2–G\(\beta\gamma\). (A) GRK2–G\(\beta\gamma\)·CCG2224061, carbon atoms for ligand are shown in cyan. (B) GRK2–G\(\beta\gamma\)·CCG257284, carbon atoms for ligand are shown in light blue. (C) GRK2–G\(\beta\gamma\)·CCG258748, carbon atoms for ligand are shown in green. Hydrogen bonds are shown as black dashed lines and backbone nitrogens are shown as blue spheres.

Figure 4. Structural comparison of analogous GRK2–G\(\beta\gamma\) complexes with indazole- or benzodioxole-substituted paroxetine derivatives. Key structural changes in the P-loop and/or \(\alpha\)B-\(\alpha\)C loop are highlighted with red circles and black dashed lines linking \(\text{C}\alpha\) carbons with the greatest displacement in each region discussed in the text. A) GRK2–G\(\beta\gamma\)·CCG224061 is shown in cyan and GRK2–G\(\beta\gamma\)·paroxetine (PDB ID: 3V5W) in gray. B) GRK2–G\(\beta\gamma\)·CCG257284 is
shown in blue and GRK2–Gβγ·CCG211998 (PDB ID: 5UKK) in magenta. C) GRK2–Gβγ·CCG258748 is shown in green and GRK2–Gβγ·CCG258208 (PDB ID: 5UKM) in orange.

**Figure 5.** Principal component analysis (PCA) of GRK and PKA structures. PC1 represents the opening and closing of the small and large lobes at the hinge, whereas PC2 corresponds to a smaller twisting motion of the small lobe relative to the large lobe. Circles indicate the PCA coordinates for the kinase domains in deposited crystal structures of GRKs and PKA: kinase domain (KD)-closed and -open GRK4 subfamily members (black and red, respectively), GRK1 (blue), and closed and open PKA (gray and pink). GRK2–Gβγ complexes with compounds containing a benzodioxole or an indazole warhead are shown in bright yellow and green, respectively. The remaining GRK2 structures are indicated in dark green. Key structures are labelled with their PDB codes (for previously published structures) or compound codes (for new structures reported in this paper). The axes indicate the displacement from the mean conformation along either PC1 or PC2, with numbers in axis labels showing the percentage of total structural variance captured by PC1 or PC2.

**Scheme 1.** Synthesis of intermediate 7. Reagents and conditions: a) AcOH, H2SO4, 0°C, then NaNO2, b) 20% HNO3, 45°C, c) 10% Pd/C, H2, EtOH, THF, d) KOAc, Ac2O, CHCl3, 0°C then isoamyl nitrite and 80°C, e) 6N HCl, MeOH, f) TBSCl, DIEA, imidazole, DCM, g) Boc2O, DIEA, DMAP, THF, h) TBAF, THF
**Scheme 2.** Synthesis of indazole-substituted paroxetine hybrids. Reagents and conditions: a) Ms₂O, DIEA, DCM, b) NaH, DMF, 7a or 7b, c) 1N NaOH, MeOH, d) DIEA, EDC, HOBr, R₂NH₂, e) HCl/dioxanes

**Scheme 3.** Synthesis of analogues 17a-e. Reagents and conditions: a) K₂CO₃, EtI, DMF, b) NaCNBH₃, Acetone, THF, AcOH, c) Ms₂O, DIEA, DCM, d) NaH, DMF, 7a or 7b, e) 4M HCl/Dioxanes, f) 20% TFA/DCM
Tables

Table 1. Kinase Activity and Half-Life in Mouse Liver Microsomes of Indazole-Paroxetine Hybrids

<table>
<thead>
<tr>
<th>CCG#</th>
<th>R&lt;sup&gt;1&lt;/sup&gt;</th>
<th>R&lt;sup&gt;2&lt;/sup&gt;</th>
<th>GRK2 IC&lt;sub&gt;50&lt;/sub&gt; (µM)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>GRK1 IC&lt;sub&gt;50&lt;/sub&gt; (µM)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>GRK5 IC&lt;sub&gt;50&lt;/sub&gt; (µM)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>PKA IC&lt;sub&gt;50&lt;/sub&gt; (µM)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>ROCK&lt;sub&gt;1&lt;/sub&gt;&lt;sup&gt;b&lt;/sup&gt; (%)</th>
<th>MLM t&lt;sub&gt;1/2&lt;/sub&gt; (min)</th>
</tr>
</thead>
<tbody>
<tr>
<td>224061</td>
<td>H</td>
<td>H</td>
<td>0.066 (1.1)</td>
<td>6.4 (1.3)</td>
<td>1.3 (1.2)</td>
<td>3.1 (1.4)</td>
<td>100±1.5</td>
<td>30</td>
</tr>
<tr>
<td>258002</td>
<td>H</td>
<td>F</td>
<td>0.13 (1.6)</td>
<td>3.6 (1.3)</td>
<td>0.81 (1.2)</td>
<td>3.4 (1.6)</td>
<td>48±5.8</td>
<td>22</td>
</tr>
<tr>
<td>232406</td>
<td>H</td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>0.36 (1.8)</td>
<td>&gt;100</td>
<td>28.8 (1.7)</td>
<td>9.8 (1.2)</td>
<td>63±6.2</td>
<td>8.3</td>
</tr>
<tr>
<td>258003</td>
<td>F</td>
<td>R&lt;sup&gt;1&lt;/sup&gt;</td>
<td>0.36 (1.7)</td>
<td>40.1 (1.1)</td>
<td>8.0 (1.2)</td>
<td>24 (1.9)</td>
<td>80±8.4</td>
<td>13</td>
</tr>
<tr>
<td>257284</td>
<td>R&lt;sup&gt;2&lt;/sup&gt;</td>
<td>H</td>
<td>0.10 (1.2)</td>
<td>3.9 (1.5)</td>
<td>0.49 (1.1)</td>
<td>15 (1.3)</td>
<td>100±5.7</td>
<td>2.7</td>
</tr>
<tr>
<td>258748</td>
<td>R&lt;sup&gt;1&lt;/sup&gt;</td>
<td>H</td>
<td>0.008 (1.3)</td>
<td>4.4 (1.3)</td>
<td>0.24 (1.2)</td>
<td>62 (1.6)</td>
<td>83±2.4</td>
<td>8.1</td>
</tr>
</tbody>
</table>

<sup>a</sup>All IC<sub>50</sub> measurements are reported as the geometric mean of three separate experiments run in duplicate. Error is expressed in parenthesis as the geometric standard deviation factor (multiplied or divided by the mean).<br><sup>b</sup>Percent inhibition at an inhibitor concentration of 10 µM, error is expressed as the standard deviation.
Table 2. Kinase Activity of Alkylated Indazole-Paroxetine Hybrids

<table>
<thead>
<tr>
<th>CCG#</th>
<th>R</th>
<th>GRK2 IC$_{50}$ (µM)$^a$</th>
<th>GRK1 IC$_{50}$ (µM)$^a$</th>
<th>GRK5 IC$_{50}$ (µM)$^a$</th>
<th>PKA IC$_{50}$ (µM)$^a$</th>
<th>ROCK1$^b$ (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>224061</td>
<td>H</td>
<td>0.066 (1.1)</td>
<td>6.4 (1.3)</td>
<td>1.3 (1.2)</td>
<td>3.1 (1.4)</td>
<td>100±1.5</td>
</tr>
<tr>
<td>258001</td>
<td>Me</td>
<td>0.28 (1.5)</td>
<td>52 (1.1)</td>
<td>33 (1.2)</td>
<td>85 (1.2)</td>
<td>61±5.3</td>
</tr>
<tr>
<td>258211</td>
<td>Et</td>
<td>0.96 (1.3)</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>45±1.5</td>
</tr>
<tr>
<td>258746</td>
<td>iPr</td>
<td>1.8 (1.2)</td>
<td>&gt;100</td>
<td>&gt;100</td>
<td>NT</td>
<td>33±10.3</td>
</tr>
</tbody>
</table>

$^a$All IC$_{50}$ measurements are reported as the geometric mean of three separate experiments run in duplicate. Error is expressed in parenthesis as the geometric standard deviation factor (multiplied or divided by the mean). $^b$Percent inhibition at an inhibitor concentration of 10 µM, error is expressed as the standard deviation.
### Table 3. Mouse Cardiomyocyte Contractility

<table>
<thead>
<tr>
<th>Concentration</th>
<th>DMSO</th>
<th>0.5 µM</th>
<th>1 µM</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Baseline before isoproterenol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>max contraction (% cell length)</td>
<td>4.6 ± 0.7</td>
<td>4.5 ± 0.8</td>
<td>6.4 ± 0.6</td>
</tr>
<tr>
<td><strong>After isoproterenol</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>max contraction (% cell length)</td>
<td>11 ± 1.7</td>
<td>16 ± 1.1</td>
<td>17 ± 1.2*</td>
</tr>
<tr>
<td>% increase in contraction</td>
<td>150 ± 45</td>
<td>280 ± 92</td>
<td>180 ± 26</td>
</tr>
</tbody>
</table>

Values represent the mean contraction amplitude (as a percentage of cell length) ± standard error of the mean for 6-8 cardiomyocytes. Statistical significance (*p < 0.05) was determined in comparison to the DMSO control by a one-way ANOVA followed by Dunnet’s test.
Table 4. *In vivo* Exposure Following 10 mg/kg Intraperitoneal Administration in Mice

<table>
<thead>
<tr>
<th>Time (hr)</th>
<th>[224061] (ng/mL)</th>
<th>AUC&lt;sub&gt;0-7h&lt;/sub&gt; (ng·hr/mL)</th>
<th>AUC&lt;sub&gt;0-∞&lt;/sub&gt; (ng·hr/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.5</td>
<td>440±62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>93±8.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>29±7.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>13±6.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-7h&lt;/sub&gt;</td>
<td>695</td>
<td></td>
<td></td>
</tr>
<tr>
<td>AUC&lt;sub&gt;0-∞&lt;/sub&gt;</td>
<td>731</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Plasma concentrations are the mean from three mice for each time point, error is expressed as the standard deviation.
Table 5. Buried Surface Area Calculation for Paroxetine Analogs Crystallized with GRK2

<table>
<thead>
<tr>
<th>Compound</th>
<th>Hinge-binding moiety</th>
<th>Total BSA of ligand ($\text{Å}^2$)</th>
<th>BSA of hinge-binding ring ($\text{Å}^2$)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paroxetine</td>
<td></td>
<td>759</td>
<td>354</td>
</tr>
<tr>
<td>CCG211998</td>
<td>Benzodioxole</td>
<td>1056</td>
<td>362</td>
</tr>
<tr>
<td>CCG258208</td>
<td></td>
<td>1030</td>
<td>347</td>
</tr>
<tr>
<td>CCG224061</td>
<td></td>
<td>798</td>
<td>369</td>
</tr>
<tr>
<td>CCG257284</td>
<td>Indazole</td>
<td>1051</td>
<td>368</td>
</tr>
<tr>
<td>CCG258748</td>
<td></td>
<td>1025</td>
<td>371</td>
</tr>
</tbody>
</table>
Figures and Schemes

Figure 1

**GSK180736A**
- GRK2 IC_{50} = 0.77 μM
- GRK5 IC_{50} = >100 μM
- ROCK1 IC_{50} = 0.10 μM

**Paroxetine**
- GRK2 IC_{50} = 1.38 μM
- GRK5 IC_{50} = >100 μM
- ROCK1 inh = 10% (10 μM)

**Takeda CMPD101**
- GRK2 IC_{50} = 0.03 μM
- GRK5 IC_{50} = >100 μM
- ROCK1 inh = 10% (10 μM)
Scheme 1

1 \[\xrightarrow{a, b}\] 2 \[\xrightarrow{c}\] 3 \[\xrightarrow{d, e}\] 4b

4a: R=H  
4b: R=F

5a: R=H  
5b: R=F

6a: R=H  
6b: R=F

7a: R=H  
7b: R=F
Scheme 2

8 → 9a: R₁ = H
9b: R₁ = F

9a → 10a: R₁ = H
10b: R₁ = F

10a → 11aa (CCG232406): R₁ = H, R₂ = 2,6-dimethoxybenzyl
11ab (CCG257284): R₁ = H, R₂ = pyridin-2-ylmethyl
11ac (CCG258748): R₁ = H, R₂ = (1H-pyrazol-3-yl)methyl
11b (CCG258003): R₁ = F, R₂ = 2,6-dimethoxybenzyl
Scheme 3

12

13a: R₁ = Ethyl
13b: R₁ = Isopropyl

14: R₁ = Boc
15: R₁ = Methyl

16a: R₁ = Boc, R₂ = H
16b: R₁ = Boc, R₂ = F
16c: R₁ = Methyl, R₂ = H
16d: R₁ = Ethyl, R₂ = H
16e: R₁ = Isopropyl, R₂ = H

17a (CCG224061): R₁ = H, R₂ = H
17b (CCG258002): R₁ = H, R₂ = F
17c (CCG258001): R₁ = Methyl, R₂ = H
17d (CCG258211): R₁ = Ethyl, R₂ = H
17e (CCG258746): R₁ = Isopropyl, R₂ = H